BCAB
Bioatla IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.36M
P/E Ratio
—
EPS
$-50.50
Beta
1.08
52W High
$71.50
52W Low
$5.42
50-Day MA
$9.11
200-Day MA
$24.49
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bioatla Inc
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $2.00M |
| Gross Profit (TTM) | $2.00M |
| EBITDA | $-58.93M |
| Operating Margin | -492.80% |
| Return on Equity | -814.00% |
| Return on Assets | -111.90% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $-0.60 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | 4.68 |
| EV/Revenue | 269.0 |
| EV/EBITDA | 0.30 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 31.60% |
| Shares Outstanding | $1.66M |
| Float | $49.91M |
| % Insiders | 5.63% |
| % Institutions | 20.47% |
Data last updated: 4/7/2026